[1] Von Delius S,Lersch C,Mayr M,et al. Capecitabinc for treatment of advanced hepatocellular carcinoma,Hepatogastroenterology,2007.54(80):2310-2314. [2] Qin SK,Bai Y. Phase Ⅲ study of oxalipalin plus 5-flouorouracil/leucovorin(FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients. J Clin Oncol,2010,28(15 Suppl):4008. [3] Taieb J,Bonyhay L,Golli L,et al. Gemicitabine plus osaliplatiin for patients with advanced hapatocellular caecinama using two different schedules. Cancer,2003,98(12):2664-2670. [4] 杨柳青,秦叔逵,赵宁莉,等. FOLFOX4方案治疗中晚期原发性肝癌的临床研究. 临床肿瘤学杂志,2013,18(2):108-113. [5] Uka K,Aikata H,Takaki S,et al. Systemic gemcitabine combined with intraarterial low-dose cisplatin and s-fluorouracil for advanced hepatocellular carcinoma:seven cases. World J Gastroeterol,2008,14(16):2602-2608. [6] 杨柳青,秦叔逵,华海清,等. XELOX方案治疗中晚期原发性肝癌的临床研究. 临床肿瘤学杂志,2013,18(8):704-708. [7] Hsu CH. Yang TS,Hsu C et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer,2006,102(6):981-986. [8] Asnacios A,Fartowc L,Romano O,et al, Gemecitabine plus oxaliplatin (GEMOX) combined with qtuscimat in patients with progressive advanced stage hepatocellular carcinoma:results of a multicentor phase 2 study. Cancer,2008,112(12):2733-2739. |